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Reactive lymphoid hyperplasia is a common pathological ﬁnding from lung biopsy. It is frequently the
original pathologic interpretation from FNA or core biopsies of lesions that are ultimately determined to
be non-neoplastic pulmonary lymphoid disorders. One of these disorders is Castleman’s Disease. We
present a case of a 35-year-old male who underwent multiple procedures to diagnose a posterior
mediastinal mass. This was eventually diagnosed as Castleman’s Disease. We review the pathology of
reactive lymph node hyperplasia and the spectrum of non-neoplastic pulmonary lymphoid disorders. We
also review the Unicentric hyaline vascular variant form of Castleman’s disease.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Reactive lymphoid hyperplasia is a common pathologic ﬁnding
from ﬁne needle aspirates and core biopsies of peripheral lymph
nodes. It is also a common ﬁnding from parenchymal lung and
mediastinal lymph node biopsies. This histological ﬁnding should
prompt the clinician to consider the spectrum of non-neoplastic
pulmonary lymphoid lesions. One cause of reactive lymphoid
hyperplasia is Castleman’s disease which was the ﬁnal diagnosis in
our case. Herein we brieﬂy discuss the differential of reactive
lymphoid hyperplasia in the setting of pulmonary lymph node
biopsy and focus on non-neoplastic pulmonary lymphoid disorders.
We also provide a brief review of unicentric hyaline vascular variant
of Castleman’s disease (U-HVV).
2. Case report
A 35 year-old Argentinean male was referred to pulmonary
clinic for work-up of an abnormal chest x-ray (Fig. 1). The patient
had a 15-year history of cough productive of brown sputum
without any hemoptysis. The patient immigrated from Argentina
ﬁve years prior to presentation. He reported no exposure to
tuberculosis or placement of a PPD. He worked as a butcher for 15
years and denied smoking. Ten months prior to evaluation he
suffered a clavicular fracture due to a motor cycle accident. At that: þ1 614 293 5503.
).
rved.time, he was noted to have a large posterior mediastinal mass on
chest x-ray. A chest CT revealed a heterogeneous 15  20 cm par-
aspinal mass (Fig. 2). He underwent a CT guided biopsy using an 18
G core biopsy needle. Pathology results demonstrated a paucity of
normal lung tissue, but prominent lymphoid tissue without
molecular evidence of a B-cell lymphoproliferative disorder.
Preoperative pulmonary function tests (PFTs), serum chemistries,
cell blood count, liver function tests and LDH were normal. A CT of
the abdomen was normal without evidence of lymphadenopathy.
A video assisted thoracoscopic (VATS) biopsy was performed at
which time the mass was noted to be 15  20 cm and extending to
the posterior parietal pleura adjacent to the vertebral bodies and
the esophagus. Grossly, the mass was very vascular and had
a thickened, white peel. Due to the vascularity and concern for
bleeding the patient underwent multiple Tru-cut core biopsies.
Intraoperative frozen section was concerning for lymphoma. His
postoperative course was uncomplicated and he was discharged to
home. Pathology revealed fragments of reactive appearing
lymphoid tissue. Given the lack of deﬁnitive diagnosis, location and
size of the mass, it was felt that complete surgical resection would
be required. Therefore, the patient underwent a right thoracotomy
with resection of the mass. Intraoperatively, there was concern for
extension to the T6 neural foramina and a neurosurgical consul-
tation was obtained to assist with dissection of the mass from the
nerve root. The patient’s hospital course was uncomplicated and he
was discharged to home. Final pathology revealed Castleman’s
disease, hyaline vascular type (Fig. 3). Molecular studies did iden-
tify a monoclonal T-cell proliferation of unknown signiﬁcance.
Fig. 3. 400X magniﬁcation of a surgical pathology specimen obtained demonstrates
the characteristic atrophic germinal center surrounded by concentric zones of
lymphocytes. This appearance is referred to as ‘‘onion-skin’’ which is identiﬁed by the
arrow.Fig. 1. A chest radiograph demonstrates a large posterior mediastinal mass.
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The incidence of reactive lymphoid hyperplasia from needle
guided biopsy of pulmonary parenchyma or thoracic lymphade-
nopathy has not been reported. In almost all cases this ﬁnding
prompts the clinician to obtain further surgical samples to deﬁne
the process. Reactive lymphoid hyperplasia (RLH) has been
described as the benign and reversible enlargement of lymphoid
tissue secondary to antigen stimulus.1 There are four patterns
which can be seen in RLH: Follicular Pattern, Diffuse Paracortical
Hyperplasia, Sinus Histiocytosis and Mixed Pattern.1 Each of these
morphologic patterns has an associated differential diagnosis that
pathologists entertain for the etiology of reactive lymphoid
hyperplasia. Unfortunately, the ability to clearly distinguish these
patterns within the lymph node occurs in less than 10% of cases.1
More often, the primary goal becomes differentiating benign vs.
malignant potential of the tissue. It is often possible using immu-
nohistochemical and molecular analysis to exclude clonality of the
tissue, which in the majority of cases excludes malignancy.2Fig. 2. A CT scan of the chest demonstrated a large heterogeneously enhancing
posterior mediastinal mass.When faced with histological ﬁndings of reactive lymphoid
hyperplasia the differential diagnosis can be narrowed to non-
neoplastic lymphoid lesions. A table summarizing key features of
these disorders is listed below as Table 1.3,4 The chest physician can
use a basic algorithm to help narrow their differential diagnosis for
this pathological ﬁnding. The ﬁrst step is to critique the appearance
of the lesion on imaging and from surgical evaluation. If the lesion
has the appearance of a solitary lung mass then the differential can
be narrowed to an intrapulmonary lymph node, Plasma cell gran-
uloma, pseudolymphoma or as in our case, Castleman’s Disease.3,4
If the lesion has a poorly deﬁned interstitial or alveolar appearance
then the etiology is typically follicular bronchiolitis or lymphocytic
interstitial pneumonia.3,4
A rare disease, also referred to as giant lymph node hyperplasia,
angiofollicular lymph node hyperplasia and benign lymph node
lymphoma, Castleman’s Disease was ﬁrst described in 1959 by
Castleman5 and colleagues. A patient presented with fevers and
weakness and was found to have a mediastinal mass. Surgical
resection revealed lymphadenopathy whose characteristic archi-
tecture is still used to deﬁne Castleman’s disease.
There are three types of Castleman’s disease: unicentric
hyaline vascular variant, unicentric plasma cell variant and mul-
ticentric plasma cell variant.6 Discussion will be limited to theTable 1
Characteristics of non-neoplastic pulmonary lymphoid disorders.
Disease Common features Age at time
of onset
(years)
Constitutional
signs
Intrapulmonary
lymph node
Solitary/multiple lung
or mediastinal masses
Any age No
Plasma cell
granuloma
Solitary lung mass 10–30 No
Pseudolymphoma Solitary lung mass 30–70 No
Castleman’s Disease –
U-HVV
Solitary mass in middle
or posterior mediastinum
20–30 No
Follicular
bronchiolitis
Bilateral reticular or
reticulonodular
inﬁltrates
Depends on
underlying
cause
Yes – dyspnea,
obstructive PFTs
Lymphoid interstitial
pneumonia
Ground glass opacities,
nodular lesions and
rarely cysts
40–70 Yes – cough,
dyspnea, wt loss.
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plasma cell variant has a much different presentation with
systemic symptoms. In U-HVV, the overall number of lymphoid
follicles is increased. The atrophic germinal centers are sur-
rounded by concentric zones of small lymphocytes yielding an
‘‘onion-skin’’ appearance6 seen in Fig. 3. Due to the similarity of
the histopathologic pattern to lymph nodes seen in viral or
inﬂammatory disorders, the disease was originally attributed to
an undeﬁned inﬂammatory process.5 The current thought is that
the pathogenesis of Castleman’s Disease is multifactorial,
involving viral stimulation (HHV-8), angiogenesis and cytokine
(IL-6) production.6 There are no studies demonstrating a clonal
immunoglobin or T-cell receptor gene rearrangement in the
pathologic samples that were deﬁned as CD7 thus enabling the
classiﬁcation within the spectrum of non-neoplastic pulmonary
lymphoid disorders.
Clinically, the median age of presentation of U-HVV Castle-
man’s Disease is 35 years with no predilection towards either
gender.8 There is typically a single node or chain of lymph nodes
involved. The most common locations are mediastinum, cervical,
abdominal and axillary lymph nodes.8 There are very few reports
of systemic symptoms (<10%) compared to symptoms of fevers,
night sweats that can be seen with the unicentric plasma cell or
the multicentric plasma cell variants. In U-VHH the symptoms
typically reﬂect the compression of the mass against adjacent
structures.
Diagnosis is best achieved by excisional biopsy. Due to the
normal appearance of cells from the lymph node along with the
normal clonality of those cells, ﬁne needle aspirates and core
biopsies typically fail to diagnose U-HVV Castleman’s Disease.9 In
one case series, frozen section review revealed the correct diag-
nosis in only 50% of cases.10 Preserving the architecture of the entire
germinal center and interfollicular zone is paramount. In our case, it
was likely that the architecture was disrupted with the core needle
biopsies in the original two procedures and thus the diagnosis was
unable to be made.
Treatment of U-VHH Castleman’s Disease is by surgical excision,
which is almost always curative.11 Due to the size at presentation
and the vascular appearance, surgical resection has been primarily
performed through thoracotomy. The 5 year survival rate is 100%with only a few case reports documenting reoccurrence of U-VHH
Castleman’s Disease.104. Summary
We provide a basic approach for the chest physician to formu-
late a differential diagnosis for reactive lymphoid hyperplasia from
lung biopsy. This differential focuses on the non-neoplastic
pulmonary lymphoid disorders. Castleman’s disease is part of this
list and should be considered for any asymptomatic mediastinal
masses that are interpreted as reactive lymphoid hyperplasia from
FNA or core needle biopsy.
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